More insurance plans than ever are offering Taltz as the Preferred IL-17A antagonist across Commercial and Part D.

Learn more

Dermatology Efficacy

Results at week 12

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz is the first FDA-approved IL-17A antagonist that includes PASI 100 in the Prescribing Information1

In UNCOVER-2, 83% of patients taking Taltz achieved sPGA 0,1 vs 2% who received placebo.

ADDITIONAL WEEK 12 RESULTS

In UNCOVER-1 (Taltz n=433; placebo n=431) and UNCOVER-3 (Taltz n=385; placebo n=193), Taltz patients achieved similar results: 89% and 87% of Taltz patients achieved PASI 75 vs 4% and 7% for placebo. Additionally, 71% and 68% of Taltz patients achieved PASI 90 vs 1% and 3% for placebo, and 35% and 38% of Taltz patients achieved PASI 100 vs 0% and 0% for placebo. Also, 82% and 81% of Taltz patients achieved sPGA 0,1 vs 3% and 7% for placebo.

Trial design

SELECT IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

Efficacy you can see

Week 60 results

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Reassure your patients that consistent results can be maintained with Taltz at week 601

Trial design

SELECT IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

Week 264 results

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Consistent range of response through 5 years, mNRI and observed9

Induction period and open-label extension

*Nx=observed population.

A subset of patients from UNCOVER-3 who received a 160 mg starting dose of Taltz at week 0, followed by 80 mg every 2 weeks through week 12, followed by 80 mg every 4 weeks, is shown.

The open-label phase of the study beginning after week 12 has limitations (e.g., no placebo comparison, patients remaining in the extension phase may be those with better results).

In an mNRI analysis of patients receiving Taltz at week 60, 89% of patients achieved PASI 75, 78% of patients achieved PASI 90, and 59% of patients achieved PASI 100. In an mNRI analysis of patients receiving Taltz at weeks 108, 156, 204, and 264, 84%, 82%, 83%, and 79% of patients, respectively, achieved PASI 75; 71%, 69%, 66%, and 67% of patients, respectively, achieved PASI 90; and 50%, 49%, 48%, and 46% of patients, respectively, achieved PASI 100.

mNRI of intent-to-treat population through week 264.

mNRI analysis imputes missing data due to study drug (eg, inadequate response, adverse event, lack of efficacy) as nonresponse; whereas missing data due to other reasons (eg, missed visits, lost to follow-up) is included as a predicted value based on statistical modeling of observed data.

mNRI=modified nonresponder imputation.

Trial design

SELECT IMPORTANT SAFETY INFORMATION
INFECTIONS
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Rapid clearance by week 12 that was sustained through week 26410

Post hoc observed analyses of ITT population through week 264.

In UNCOVER-1, patients receiving Taltz achieved a mean PASI of 1.9 (an 88% improvement from the mean baseline score of 20.1) at week 12. Patients receiving placebo achieved a mean PASI of 18.9 (a 3% improvement from the mean baseline score of 20.3) at week 12.

In UNCOVER-2, patients receiving Taltz achieved a mean PASI of 1.7 (a 91% improvement from the mean baseline score of 19.4) at week 12. Patients receiving placebo achieved a mean PASI of 19.1 (a 7% improvement from the mean baseline score of 20.6) at week 12.

A subset of patients from UNCOVER-3 who received a 160 mg starting dose of Taltz at week 0, followed by 80 mg every 2 weeks through week 12, followed by 80 mg every 4 weeks, is shown. Patients and site personnel were blinded to study treatment until all patients completed week 12 or discontinued. The open-label extension phase of the study has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those with better results).

SELECT IMPORTANT SAFETY INFORMATION
PRE-TREATMENT EVALUATION FOR TUBERCULOSIS
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Trust Taltz to offer

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

A Chance for Complete Clearance1,11,12

Complete and consistent clearance across all 3 UNCOVER trials

Click here for data

Durable Efficacy13

Sustained response through 5 years

Click here for data

Rapid Response5

Patients achieved rapid response as early as week 12

Click here for data

SELECT IMPORTANT SAFETY INFORMATION
HYPERSENSITIVITY
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

References: 1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020. 2. Data on file. Lilly USA, LLC. TAL20160223C. 3. Data on file. Lilly, USA, LLC. TAL20160328C. 4. Data on File. Lilly USA, LLC. TAL20160222D. 5. Data on File. Lilly USA, LLC. TAL20160222A. 6. Data on File. Lilly USA, LLC. TAL20160222E. 7. Data on File. Lilly USA, LLC. TAL20160222B. 8. Data on file. Lilly USA, LLC. DOF-IX-US-0274. 9. Data on file. Lilly USA, LLC. DOF-IX-US-0197. 10. Data on file. Lilly USA, LLC. DOF-IX-US-0232. 11. Data on file. Lilly USA, LLC DOF-IX-US-0237. 12. Blauvelt A, Lebwohl MG, Mabuchi T, Leung A, Garrelts A, Crane H, ElMaraghy H, Patel H, Ridenour T, See K, Gallo G, Paul C. Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2020 Nov 28:S0190-9622(20)33053-X. doi: 10.1016/j.jaad.2020.11.022. Epub ahead of print. PMID: 33253833. 13. Data on file. Lilly USA, LLC. DOF-IX-US-0271. 14. Data on file. Lilly USA, LLC. DOF-IX-US-0259. 15. Data on file. Lilly USA, LLC. DOF-IX-US-0258. 16. Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A; IXORA-Q Study Group. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018 Oct;179(4):844-852. doi: 10.1111/bjd.16736. Epub 2018 Jul 22. PMID: 29747232. 17. Data on file. Lilly USA, LLC. DOF-IX-US-0263.

INDICATIONS

Taltz is indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is also indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

Immunizations
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.

Please click to access the Prescribing Information and Medication Guide . Please see Instructions for Use included with the device.

IX HCP ISI 07MAY2020